LTRN Stock Analysis: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$1.12
-0.97 (-46.41%)
▼
5d:
-47.42%
30d:
-60.56%
90d:
-67.81%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LTRN is down 47.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LTRN is down 47.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $1.12, which is considered oversold relative to its 30-day fair value range of $2.15 to $2.86.
Technical Outlook: Technically, LTRN is in a strong downtrend. The price is currently testing key support at $1.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 46.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1685.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LTRN is in a strong downtrend. The price is currently testing key support at $1.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 46.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1685.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.15 -
$2.86
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-46.4%)
- BULLISH: Trading 1685.7% below Wall St target ($20.00)
- WARNING: Recommendation downgraded due to -47.4% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.15 -
$2.86
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.55
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.59
Wall Street Target
$20.00
(+1685.7%)
Share & Embed Analysis
Last updated: March 30, 2026 8:30 AM ET
Data refreshes hourly during market hours. Next update: 9:30 AM
Data refreshes hourly during market hours. Next update: 9:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 65 BUY |
